Monoclonal Gammopathies of Indetermined Significance: Diagnosis and Clinical Follow-up Guidelines

被引：0

作者：

Parreira, Joana ^{[1
]}

Lucio, Paulo ^{[2
]}

Joao, Cristina ^{[3
]}

Macedo, Ana ^{[4
,5
]}

Sarmento, Ana Bela ^{[6
,7
]}

Geraldes, Catarina ^{[6
,7
]}

Goncalves, Cristina ^{[8
]}

Esteves, Graca ^{[9
]}

机构：

[1] Univ Lisbon, Fac Med, Inst Portugues Oncol Francisco Gentil, Serv Hematol, P-1699 Lisbon, Portugal

[2] Fundacao Champalimaud, Unidade Hematooncol, Lisbon, Portugal

[3] Univ Lisbon, Fac Ciencias Med, Inst Portugues Oncol Francisco Gentil, Serv Hematol, P-1699 Lisbon, Portugal

[4] Ctr Hosp Algarve, Serv Hematol, Faro, Portugal

[5] Univ Beira Interior, Fac Ciencias Saude, Covilha, Portugal

[6] Centro Hosp Univ Coimbra, Serv Hematol Clin, Coimbra, Portugal

[7] Univ Coimbra, Ctr Invest Meio Ambiente Genet & Oncobiol, Fac Med, Coimbra, Portugal

[8] Hosp Santo Antonio, Serv Hematol Clin, Oporto, Portugal

[9] Ctr Hosp Lisboa Norte, Hosp Santa Maria, Serv Hematol, Lisbon, Portugal

来源：

ACTA MEDICA PORTUGUESA | 2014年 / 27卷 / 05期

关键词：

Monoclonal Gammopathy of Undetermined Significance; Prognosis; Disease Progression; Long-Term Care; Portugal; UNDETERMINED SIGNIFICANCE MGUS; MALIGNANT-TRANSFORMATION; BIOLOGICAL INSIGHTS; RISK; PROGRESSION; PREVALENCE;

D O I：

10.20344/amp.5411

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The Portuguese group of multiple myeloma of the Portuguese Society of Hematology proposes a national protocol for diagnosis and clinical follow-up of monoclonal gammopathies. The proposed protocol aims to standardize clinical management of monoclonal gammopathies. Furthermore, it would also define the major risk factors for progression to Multiple Myeloma that require a precocious close articulation between general practitioners and a Hematology Clinic.

引用

页码：661 / 664

页数：4

共 18 条

[1] Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy
Baldini, L
Guffanti, A
Cesana, BM
Colombi, M
Chiorboli, O
Damilano, I
Maiolo, AT
[J]. BLOOD, 1996, 87 (03) : 912 - 918
[2] Monoclonal gammopathy of undetermined significance: a consensus statement
Berenson, James R.
Anderson, Kenneth C.
Audell, Robert A.
Boccia, Ralph V.
Coleman, Morton
Dimopoulos, Meletios A.
Drake, Matthew T.
Fonseca, Rafael
Harousseau, Jean-Luc
Joshua, Douglas
Lonial, Sagar
Niesvizky, Ruben
Palumbo, Antonio
Roodman, G. David
San-Miguel, Jesus F.
Singhal, Seema
Weber, Donna M.
Zangari, Maurizio
Wirtschafter, Eric
Yellin, Ori
Kyle, Robert A.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (01) : 28 - 38
[3] Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications
Bianchi, Giada
Kyle, Robert A.
Colby, Colin L.
Larson, Dirk R.
Kumar, Shaji
Katzmann, Jerry A.
Dispenzieri, Angela
Therneau, Terry M.
Cerhan, James R.
Melton, L. Joseph, III
Rajkumar, S. Vincent
[J]. BLOOD, 2010, 116 (12) : 2019 - 2025
[4] Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
Cesana, C
Klersy, C
Barbarano, L
Nosari, AM
Crugnola, M
Pungolino, E
Gargantini, L
Granata, S
Valentini, M
Morra, E
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) : 1625 - 1634
[5] Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
Dimopoulos, Meletios
Kyle, Robert
Fermand, Jean-Paul
Rajkumar, S. Vincent
San Miguel, Jesus
Chanan-Khan, Asher
Ludwig, Heinz
Joshua, Douglas
Mehta, Jayesh
Gertz, Morie
Avet-Loiseau, Herve
Beksac, Meral
Anderson, Kenneth C.
Moreau, Philippe
Singhal, Seema
Goldschmidt, Hartmut
Boccadoro, Mario
Kumar, Shaji
Giralt, Sergio
Munshi, Nikhil C.
Jagannath, Sundar
[J]. BLOOD, 2011, 117 (18) : 4701 - 4705
[6] Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study
Dispenzieri, Angela
Katzmann, Jerry A.
Kyle, Robert A.
Larson, Dirk R.
Melton, L. Joseph, III
Colby, Colin L.
Therneau, Terry M.
Clark, Raynell
Kumar, Shaji K.
Bradwell, Arthur
Fonseca, Rafael
Jelinek, D. F.
Rajkumar, S. Vincent
[J]. LANCET, 2010, 375 (9727) : 1721 - 1728
[7] Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies
Korde, Neha
Kristinsson, Sigurdur Y.
Landgren, Ola
[J]. BLOOD, 2011, 117 (21) : 5573 - 5581
[8] Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
Kyle, R. A.
Durie, B. G. M.
Rajkumar, S. V.
Landgren, O.
Blade, J.
Merlini, G.
Kroeger, N.
Einsele, H.
Vesole, D. H.
Dimopoulos, M.
San Miguel, J.
Avet-Loiseau, H.
Hajek, R.
Chen, W. M.
Anderson, K. C.
Ludwig, H.
Sonneveld, P.
Pavlovsky, S.
Palumbo, A.
Richardson, P. G.
Barlogie, B.
Greipp, P.
Vescio, R.
Turesson, I.
Westin, J.
Boccadoro, M.
[J]. LEUKEMIA, 2010, 24 (06) : 1121 - 1127
[9] Kyle RA, 2003, BRIT J HAEMATOL, V121, P749
[10] A long-term study of prognosis in monoclonal gammopathy of undetermined significance
Kyle, RA
Therneau, TM
Rajkumar, SV
Offord, JR
Larson, DR
Plevak, MF
Melton, L
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (08) : 564 - 569

← 1 2 →